Darren Mullins, MD
Medical Oncology · Columbia, SCNPI 1134189814
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.4%), consulting fees and education — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Beigene USA, Inc. at 45.3% of the total.
Across 78 payments — averaging $46.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene USA, Inc.$2K
- AstraZeneca$316
- Beone Medicines USA, Inc.$141
- Johnson & Johnson$131
- Novartis$126
- Bayer$122
- plus $1K from 25 others
What the payments were for
- Consulting fees$1,65045%
- Food & beverage$1,87051%
- Education$1223%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beigene USA, Inc. | 1 | $1,650 |
| AstraZeneca(2 entities) | 13 | $316 |
| Beone Medicines USA, Inc. | 2 | $141 |
| Johnson & Johnson | 3 | $131 |
| Novartis | 6 | $126 |
| Bayer | 1 | $122 |
| Merck | 5 | $119 |
| Sanofi | 1 | $101 |
| E.r. Squibb & Sons, L.L.C. | 5 | $83 |
| Jazz Pharmaceuticals Inc. | 4 | $82 |
| Daiichi Sankyo Inc. | 3 | $75 |
| Boehringer Ingelheim | 3 | $75 |
| Genentech USA, Inc. | 4 | $69 |
| Seagen Inc. | 4 | $63 |
| Pfizer | 3 | $57 |
| Bristol Myers Squibb | 3 | $54 |
| Amgen | 1 | $34 |
| Gilead | 2 | $34 |
| Rigel Pharmaceuticals, Inc. | 1 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Mirati Therapeutics, Inc. | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Agios Pharmaceuticals, Inc. | 2 | $28 |
| Incyte Corporation | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Taiho Oncology, Inc. | 1 | $23 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $21 |
| Astellas Pharma US Inc | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| W. L. Gore & Associates, Inc. | 1 | $16 |
| Exelixis Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,642 in reported general payments places this provider in the 55th percentile of 29 medical oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 67 | $949,647 |
| Lenalidomide | 20 | $269,037 |
| RevlimidLenalidomide | 14 | $215,550 |
| IbrancePalbociclib | 12 | $193,922 |
| CalquenceAcalabrutinib Maleate | 15 | $134,075 |
| Abiraterone Acetate | 29 | $47,546 |
| Anastrozole | 124 | $2,093 |
| Fentanyl | 14 | $1,144 |
| Potassium Chloride | 54 | $736 |
| Letrozole | 29 | $556 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 25 | $451 |
| Dexamethasone | 21 | $426 |
| Tamoxifen Citrate | 11 | $385 |
| Ondansetron OdtOndansetron | 24 | $290 |
| Gabapentin | 15 | $225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $18 | $949,64767 claims |
| Bristol Myers SquibbRevlimid | $54 | $215,55014 claims |
| PfizerIbrance | $57 | $193,92212 claims |
| AstraZenecaCalquence | $316 | $134,07515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 29 medical oncology providers in South Carolina.
Other medical oncology in Columbia
- Albert LockhartCharleston$54K
- Gene SaylorsCharleston$26K
- Mariam AlexanderCharleston$23K
- Theodore GourdinCharleston$21K
- John KaczmarCharleston$20K
- Eric NelsonSpartanburg$13K
- Karyn DyehouseSeneca$9K
- Kevin BeckerCharleston$9K
- Alaa MuslimaniRock Hill$9K
- Scott LindhorstCharleston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.